Results 81 to 90 of about 70,680 (286)
Advanced Experiment Design Strategies for Drug Development
Wang et al. analyze 592 drug development studies published between 2020 and 2024 that applied design of experiments methodologies. The review surveys both classical and emerging approaches—including Bayesian optimization and active learning—and identifies a critical gap between advanced experimental strategies and their practical adoption in ...
Fanjin Wang +3 more
wiley +1 more source
Apigenin, an anticancer secondary metabolite, is produced in selected organs of a few plant taxa, including chamomile (Matricaria chamomilla) flowers and parsley (Petroselinum crispum) leaves. In this study, two cultivars of chamomile (Bodegold and Zloty
Rebekah C.I. Maynard +4 more
doaj +1 more source
Combinatorial chemo-photodynamic therapy is regared as effective cancer therapy strategy, which could be realized via multiple nano-drug delivery system.
Qisan Ma +9 more
doaj +1 more source
Iowa Developments, April 2003, Vol.12, no.2 [PDF]
Resource to help educate businesses or communities about state-sponsored ...
core
(Re)defining biopharmaceutical [PDF]
Vested interests are redefining, rebranding and co-opting what is 'biopharmaceutical'. This is not just a matter of semantics-the core identity of the biotech industry and its products is at stake.
openaire +2 more sources
ABSTRACT Background Loss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting health‐related quality of life and posing a safety hazard. Methods WAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo ...
Joaquim Mullol +14 more
wiley +1 more source
Risk-Return Analysis of the Biopharmaceutical Industry as Compared to Other Industries
Background: Profits in the biopharmaceutical industry have been scrutinized in social debate. However, drawing conclusions based on industry profitability only is inappropriate as such an analysis does not account for risks faced by investors. This study
Cedric Popa +4 more
doaj +1 more source
Manufacturing Barriers to Biologics Competition and Innovation [PDF]
As finding breakthrough small-molecule drugs gets harder, drug companies are increasingly turning to “large molecule” biologics. Although biologics represent many of the most promising new therapies for previously intractable diseases, they are extremely
Price, W. Nicholson, II, Rai, Arti K.
core +2 more sources
AbstractThe biopharmaceutical industry, whose products are produced mainly by recombinant DNA technology, antibody technologies and cytotechnology, is the most important sector in industrial biotechnology, and is one of the most rapidly growing high‐tech industries.
Xianwen, Hu, Qingjun, Ma, Shuyong, Zhang
openaire +3 more sources
A comprehensive proteome and phosphoproteome atlas across nine organs of the Chinese hamster
This study presents the first comprehensive proteome and phosphoproteome atlas of the Chinese hamster across nine organs (heart, liver, lung, kidney, spleen, cerebral cortex, skeletal muscle, stomach, and testis or ovary). A total of 14 219 proteins were identified in the proteome, with 11 828 phosphorylated proteins and 47 122 phosphorylation sites ...
Luyao Zhang +15 more
wiley +1 more source

